\-\ Texto\\:\\ \ \(0\)\
\-\ bitemporal\\ hemianopsia\\ noted\ \(0\)\
\-\ radiation\\ therapy\ \(165\)\
\-\ \\â\\€\\¢\\ isointense\\ enhancing\\ hypothalamic\\ mass\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enhancing\\ tumor\\ extending\\ along\\ the\\ ependymal\\ surfaces\ \(0\)\
\-\ \\â\\€\\¢\\ enhancing\\ tumor\\ right\\ basal\\ ganglia\\ and\\ \\ corpus\\ callosum\\.\ \(0\)\
\-\ germinoma\\,\\ primary\\ intracranial\ \(0\)\
\-\ \\â\\€\\¢\\ craniopharyngioma\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\\,\\ lymphoma\ \(0\)\
\-\ \\â\\€\\¢\\ ependymoma\ \(8\)\
\-\ \\â\\€\\¢\\ langerhan\\ histiocytosis\ \(0\)\
\-\ \\â\\€\\¢\\ germinioma\ \(0\)\
\-\ \\â\\€\\¢\\ trilateral\\ retinoblastoma\ \(0\)\
\-\ 34\\ year\\ old\\ man\\ presents\\ with\\ signs\\ and\\ symptoms\\ of\\ hypo\\-thyroidism\\ and\\ evidence\\ of\\ pituitary\\ dysfunction\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ enhancing\\:\\ 0\\.2938299742478985\ \(0\)\
\-\ germinioma\\:\\ 0\\.2500361036034508\ \(0\)\
\-\ trilateral\\:\\ 0\\.2500361036034508\ \(0\)\
\-\ ependymal\\:\\ 0\\.1987325009505439\ \(0\)\
\-\ bitemporal\\:\\ 0\\.19137974266007113\ \(0\)\
\-\ langerhan\\:\\ 0\\.18981310672594198\ \(0\)\
\-\ germinoma\\:\\ 0\\.188331196259747\ \(0\)\
\-\ retinoblastoma\\:\\ 0\\.18692531543190577\ \(0\)\
\-\ hemianopsia\\:\\ 0\\.18309462688687872\ \(0\)\
\-\ hypothalamic\\:\\ 0\\.17869984857681823\ \(0\)\
\-\ surfaces\\:\\ 0\\.17869984857681823\ \(0\)\
\-\ tumor\\:\\ 0\\.1635592066068077\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.15681381699315133\ \(0\)\
\-\ dysfunction\\:\\ 0\\.1518166261466807\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.15106565678560693\ \(0\)\
\-\ callosum\\:\\ 0\\.1472671947781567\ \(0\)\
\-\ ganglia\\:\\ 0\\.14694662191846666\ \(0\)\
\-\ pituitary\\:\\ 0\\.14421864837783258\ \(0\)\
\-\ corpus\\:\\ 0\\.1425400422445849\ \(0\)\
\-\ isointense\\:\\ 0\\.14147549418488495\ \(0\)\
\-\ 34\\:\\ 0\\.13626163290532176\ \(0\)\
\-\ basal\\:\\ 0\\.1337869907857593\ \(0\)\
\-\ ependymoma\\:\\ 0\\.13206741649597628\ \(0\)\
\-\ intracranial\\:\\ 0\\.12580359321796497\ \(0\)\
\-\ signs\\:\\ 0\\.10927071419889539\ \(0\)\
\-\ extending\\:\\ 0\\.1060066332641528\ \(0\)\
\-\ along\\:\\ 0\\.10474785081269956\ \(0\)\
\-\ radiation\\:\\ 0\\.10360984281369909\ \(0\)\
\-\ and\\:\\ 0\\.09692282596993788\ \(0\)\
\-\ primary\\:\\ 0\\.09613777398186862\ \(0\)\
\-\ lymphoma\\:\\ 0\\.09311551634919528\ \(0\)\
\-\ therapy\\:\\ 0\\.08983264632749602\ \(0\)\
\-\ evidence\\:\\ 0\\.08874393202859437\ \(0\)\
\-\ metastatic\\:\\ 0\\.08574961052306891\ \(0\)\
\-\ symptoms\\:\\ 0\\.08554532137569296\ \(0\)\
\-\ noted\\:\\ 0\\.08289601594844247\ \(0\)\
\-\ man\\:\\ 0\\.08277310692161889\ \(0\)\
\-\ presents\\:\\ 0\\.07521194402338492\ \(0\)\
\-\ disease\\:\\ 0\\.0656297598819813\ \(0\)\
\-\ of\\:\\ 0\\.06119361828390935\ \(0\)\
\-\ mass\\:\\ 0\\.059721147888741596\ \(0\)\
\-\ right\\:\\ 0\\.05183616574823472\ \(0\)\
\-\ year\\:\\ 0\\.04818368650484224\ \(0\)\
\-\ old\\:\\ 0\\.04627301824165275\ \(0\)\
\-\ the\\:\\ 0\\.031197292666682964\ \(0\)\
\-\ with\\:\\ 0\\.03061509072812618\ \(0\)\
